In this issue:
Genotype-specific cancer preventative strategies for women with Lynch syndrome
Improving social needs may optimise outcomes and mitigate healthcare disparities
No benefit to HIPEC with carboplatin during secondary cytoreductive surgery for recurrent disease
Adjuvant chemotherapy may be unnecessary for stage 1 malignant ovarian germ cell tumours
PROMs not diagnostically accurate for ovarian cancer recurrence
Survival not improved with comprehensive lymphadenectomy in advanced rare histology disease
ERAS protocols allow faster chemotherapy initiation after interval surgery
Tertiary cytoreduction for recurrent disease beneficial in select patients
Postoperative outcomes of primary versus interval cytoreductive surgery
Guidelines for the management of advanced ovarian cancer patients undergoing debulking surgery
Please login below to download this issue (PDF)